ImmunityBio完成关键随机试验患者招募：评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌

美股速递02-26

ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。

这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1110407487?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-26 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110407487","market":"us","top_or_hot":-1,"title":"ImmunityBio完成关键随机试验患者招募：评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌","media":"美股速递","content":"<p>ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。</p>\n<p>这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio完成关键随机试验患者招募：评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio完成关键随机试验患者招募：评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-26 20:36 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。\n这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1110407487","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110407487","pubTimestamp":1772109384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。\n这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio Completes Patient Enrollment for Pivotal Randomized Trial: Assessing Anktiva ® Combined with BCG versus BCG alone in the treatment of BCG-newly treated non-muscular invasive bladder carcinoma in situ","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。\n这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110407487","isCrawlerRequest":true}